Medexus Pharmaceuticals Statistics
Total Valuation
MEDXF has a market cap or net worth of 73.73 million. The enterprise value is 87.68 million.
| Market Cap | 73.73M |
| Enterprise Value | 87.68M |
Important Dates
The last earnings date was Monday, June 23, 2025.
| Earnings Date | Jun 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 32.26M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +18.76% |
| Shares Change (QoQ) | +19.97% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 29.87M |
Valuation Ratios
The trailing PE ratio is 32.81 and the forward PE ratio is 12.92.
| PE Ratio | 32.81 |
| Forward PE | 12.92 |
| PS Ratio | 0.68 |
| PB Ratio | 1.41 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 3.09 |
| P/OCF Ratio | 3.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.35, with an EV/FCF ratio of 3.68.
| EV / Earnings | 39.02 |
| EV / Sales | 0.77 |
| EV / EBITDA | 4.35 |
| EV / EBIT | 6.96 |
| EV / FCF | 3.68 |
Financial Position
The company has a current ratio of 0.83, with a Debt / Equity ratio of 0.71.
| Current Ratio | 0.83 |
| Quick Ratio | 0.38 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 1.95 |
| Debt / FCF | 1.56 |
| Interest Coverage | 1.45 |
Financial Efficiency
Return on equity (ROE) is 5.45% and return on invested capital (ROIC) is 8.79%.
| Return on Equity (ROE) | 5.45% |
| Return on Assets (ROA) | 4.55% |
| Return on Invested Capital (ROIC) | 8.79% |
| Return on Capital Employed (ROCE) | 16.00% |
| Revenue Per Employee | 1.19M |
| Profits Per Employee | 24,692 |
| Employee Count | 82 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 1.17 |
Taxes
| Income Tax | -807,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +72.05% in the last 52 weeks. The beta is 2.04, so MEDXF's price volatility has been higher than the market average.
| Beta (5Y) | 2.04 |
| 52-Week Price Change | +72.05% |
| 50-Day Moving Average | 2.10 |
| 200-Day Moving Average | 2.03 |
| Relative Strength Index (RSI) | 53.72 |
| Average Volume (20 Days) | 6,176 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MEDXF had revenue of 108.33 million and earned 2.25 million in profits. Earnings per share was 0.08.
| Revenue | 108.33M |
| Gross Profit | 63.51M |
| Operating Income | 11.92M |
| Pretax Income | 1.44M |
| Net Income | 2.25M |
| EBITDA | 18.94M |
| EBIT | 11.92M |
| Earnings Per Share (EPS) | 0.08 |
Balance Sheet
The company has 23.97 million in cash and 37.18 million in debt, giving a net cash position of -13.21 million.
| Cash & Cash Equivalents | 23.97M |
| Total Debt | 37.18M |
| Net Cash | -13.21M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 52.14M |
| Book Value Per Share | 1.62 |
| Working Capital | -16.74M |
Cash Flow
In the last 12 months, operating cash flow was 24.03 million and capital expenditures -183,000, giving a free cash flow of 23.85 million.
| Operating Cash Flow | 24.03M |
| Capital Expenditures | -183,000 |
| Free Cash Flow | 23.85M |
| FCF Per Share | n/a |
Margins
Gross margin is 58.62%, with operating and profit margins of 11.00% and 2.07%.
| Gross Margin | 58.62% |
| Operating Margin | 11.00% |
| Pretax Margin | 1.33% |
| Profit Margin | 2.07% |
| EBITDA Margin | 17.48% |
| EBIT Margin | 11.00% |
| FCF Margin | 22.02% |
Dividends & Yields
MEDXF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.76% |
| Shareholder Yield | n/a |
| Earnings Yield | 3.05% |
| FCF Yield | 32.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 19, 2018. It was a reverse split with a ratio of 0.0666666.
| Last Split Date | Dec 19, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.0666666 |
Scores
MEDXF has an Altman Z-Score of 0.47 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.47 |
| Piotroski F-Score | 5 |